Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET

Company Participants

Allison Wey - SVP, IR & Corporate Communications
Paul Edick - Chairman & CEO
Steven Pieper - CFO

Conference Call Participants

Oren Livnat - H.C. Wainwright & Co.
Roanna Ruiz - Leerink Partners
Rohan Mathur - Oppenheimer
Kelly Close - Analyst

Operator

Hello, everyone, and welcome to the Xeris Biopharma First Quarter 2024 Financial Results Conference Call and Webcast. My name is Seth, and I'll be the operator for your call today.

[Operator Instructions]. I will now hand the floor over to Allison Wey to begin the call. Please go ahead when you're ready.

Allison Wey

Thank you, John. Good morning and welcome to Xeris' first quarter 2024 financial result conference call and webcast. This morning, we issued our press releases, which can be found on our website. We're joined this morning by Paul Edick; Chairman and CEO, and Steve Pieper; our CFO. After our prepared remarks, we will open the lines for questions.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning the company's future expectations, plans, prospects, and financial performance. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those forward-looking statements.

For more information on such risks, please refer to our earnings press release and risk factors included in our SEC filings in our annual report on Form 10-K that will be filed following this call. Any forward-looking statements in this call represent our views only as of the date of this call and subject to applicable law. We disclaim any obligations to update such statements.

I'll now turn the call over to Paul.

Paul Edick

Thanks, Allison. Good morning, everyone, and thank you for joining us today. Let me start again by thanking everyone who contributed in some meaningful way to us delivering an outstanding quarter for the company, including the patients we serve, the healthcare providers we enable, and a dedicated Xeris team that executes at a high level every day.

The headline for today's call was 22% growth in total revenue versus last year, with momentum already building in the second quarter, giving us confidence to tighten our total revenue guidance, raising the bottom from $170 million to $175 million, making for a great start to 2024. At a high level, we have continued our strong commercial performance across all three of our products. Recorlev, Gvoke, and Keveyis together grew net sales by a combined 25% in the first quarter compared to last year.